+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Market Spotlight: Celiac Disease

  • Report

  • 25 Pages
  • March 2021
  • Region: Global
  • Citeline
  • ID: 4533530
This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, recent events and analyst opinion, clinical trials, upcoming events, probability of success, and a 10-year disease prevalence forecast.

Key Takeaways

  • The publisher estimates that in 2019, there were approximately 121.1 million seropositive prevalent cases of celiac disease and 48.0 million prevalent cases of biopsy-proven celiac disease worldwide.
  • Pooled seroprevalence is estimated to be 1.4%, and the pooled prevalence of biopsy-proven disease is estimated to be 0.7% worldwide.
  • Half of the industry-sponsored drugs in active clinical development for celiac disease are in Phase II, with only one drug in Phase III.
  • Therapies in development for celiac disease focus on targets such as zonulin and zonulin receptor, interleukin-15/interleukin-15 receptor, and gluten. Pipeline drugs for celiac disease are administered via the oral and intravenous routes.
  • The release of topline Phase III trial results for INN-202 is the only high-impact upcoming event in the celiac disease space. The overall likelihood of approval of a Phase I autoimmune/immunology asset is 11.9%, and the average probability a drug advances from Phase III is 66.1%. Drugs, on average, take 9.2 years from Phase I to approval in the overall autoimmune/immunology space.
  • All clinical trials for celiac disease have been in either Phase I or Phase II.
  • The US has the highest number of celiac disease clinical trials globally. Clinical trial activity in the celiac disease space is dominated by completed trials. 9 Meters Biopharma has the highest number of completed clinical trials for celiac disease, with six trials.
  • 9 Meters Biopharma leads industry sponsors with the highest overall number of clinical trials for celiac disease.

Table of Contents

OVERVIEWKEY TAKEAWAYS
DISEASE BACKGROUND
  • Subtypes

TREATMENTEPIDEMIOLOGYPIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
  • TAK-101 for Celiac Disease (October 21, 2019)

KEY UPCOMING EVENTSPROBABILITY OF SUCCESS
CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHYAPPENDIX
LIST OF FIGURES
Figure 1: Overview of pipeline drugs for celiac disease in the US
Figure 2: Pipeline drugs for celiac disease, by company
Figure 3: Pipeline drugs for celiac disease, by drug type
Figure 4: Pipeline drugs for celiac disease, by classification
Figure 5: TAK-101 for Celiac Disease (October 21, 2019): Phase IIa - Safety & Efficacy
Figure 6: Key upcoming events in celiac disease
Figure 7: Probability of success in the autoimmune/immunology pipeline
Figure 8: Clinical trials in celiac disease
Figure 9: Top 10 drugs for clinical trials in celiac disease
Figure 10: Top 10 companies for clinical trials in celiac disease
Figure 11: Trial locations in celiac disease
Figure 12: Celiac disease trials status
Figure 13: Celiac disease trials sponsors, by phase
LIST OF TABLES
Table 1: Prevalent cases of celiac disease, by definition, 2019
Table 2: Prevalence of celiac disease, by definition
Table 3: Pipeline drugs for celiac disease in the US
Table 4: TAK-101 for Celiac Disease (October 21, 2019)